Kolon TissueGene, Inc. (950160.KQ)
KRW 23000.0
(-5.35%)
KRW 23000.0
(-5.35%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 3.7 Billion | 9.45 Billion | 4 Billion | 3.55 Billion | 3.03 Billion |
| Cost of Revenue | 3.29 Billion | 1.76 Billion | 3.56 Billion | 3.17 Billion | 2.79 Billion |
| Gross Profit | 413.2 Million | 7.69 Billion | 438.28 Million | 376.92 Million | 240.37 Million |
| Operating Expenses | 20.91 Billion | 23.99 Billion | 47.34 Billion | 41.93 Billion | 45.41 Billion |
| Selling, General and Administrative Expenses | 8.93 Billion | 9.94 Billion | 11.15 Billion | 19.34 Billion | 19.17 Billion |
| Research and Development Expenses | 5.63 Billion | 7.12 Billion | 29.88 Billion | 15.72 Billion | 19.09 Billion |
| Other Expenses | 6.34 Billion | 4.67 Billion | 249.99 Million | -79.74 Million | 7.15 Billion |
| Cost and Expenses | 24.21 Billion | 25.75 Billion | 50.9 Billion | 45.11 Billion | 48.21 Billion |
| Operating Income | -20.5 Billion | -16.3 Billion | -46.9 Billion | -41.55 Billion | -45.17 Billion |
| Interest Expense | 285.82 Million | 371.18 Million | 466.45 Million | 835.25 Million | 1.17 Billion |
| Income Tax Expense | 253.14 Million | 1.31 Billion | 218.27 Million | 123.68 Million | 51.76 Million |
| Earnings before Tax | -16.97 Billion | -9.82 Billion | -47.15 Billion | -41.66 Billion | -49.93 Billion |
| Net Income | -17.22 Billion | -11.13 Billion | -47.36 Billion | -41.78 Billion | -49.98 Billion |
| Earnings Per Share Basic | -240.20 | -168.00 | -773.60 | -684.40 | -818.20 |
| Earnings Per Share Diluted | -240.20 | -168.00 | -773.60 | -684.40 | -818.20 |
| Weighted Average Shares Outstanding | 71.7 Million | 66.28 Million | 61.23 Million | 61.05 Million | 61.09 Million |
| Weighted Average Shares Outstanding (Diluted) | 71.7 Million | 66.28 Million | 61.23 Million | 61.05 Million | 61.09 Million |
| Gross Margin | 0.11 | 0.81 | 0.11 | 0.11 | 0.08 |
| EBIT Margin | -4.12 | -0.82 | -11.22 | -11.02 | -15.64 |
| Profit Margin | -4.65 | -1.18 | -11.83 | -11.75 | -16.47 |
| EBITDA | -15.27 Billion | -7.78 Billion | -45.13 Billion | -39.18 Billion | -47.46 Billion |
| Earnings Before Tax Margin | -5.53 | -1.72 | -11.72 | -11.69 | -14.89 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 958.81 Million | 1.21 Billion | 3.7 Billion | 772.2 Million | 1.75 Billion | 661.44 Million |
| Cost of Revenue | 858.93 Million | 1.05 Billion | 3.29 Billion | 701.64 Million | 1.56 Billion | 586.51 Million |
| Gross Profit | 99.87 Million | 160.03 Million | 413.2 Million | 70.55 Million | 186.94 Million | 74.93 Million |
| Operating Expenses | 5.48 Billion | 4.4 Billion | 20.91 Billion | 5.6 Billion | 5.37 Billion | 5.44 Billion |
| Selling, General and Administrative Expenses | 3.02 Billion | 2.09 Billion | - | 2.07 Billion | 2.6 Billion | 2.37 Billion |
| Research and Development Expenses | 1.41 Billion | 987.95 Million | - | 2.17 Billion | 1.08 Billion | 1.33 Billion |
| Other Expenses | -133.91 Million | 337.47 Million | 1.35 Billion | 1.2 Billion | 142.05 Million | 367 Thousand |
| Cost and Expenses | 6.33 Billion | 5.45 Billion | 24.21 Billion | 6.3 Billion | 6.93 Billion | 6.03 Billion |
| Operating Income | -5.38 Billion | -4.24 Billion | -20.5 Billion | -5.53 Billion | -5.18 Billion | -5.37 Billion |
| Interest Expense | 24.64 Million | 25.11 Million | 285.82 Million | 28.39 Million | 83.9 Million | 85.75 Million |
| Income Tax Expense | -130.69 Million | 681 Thousand | 253.14 Million | 3.5 Million | 75.95 Million | 71.51 Million |
| Earnings before Tax | -5.4 Billion | -3.78 Billion | -16.97 Billion | -3.89 Billion | -4.32 Billion | -4.85 Billion |
| Net Income | -5.27 Billion | -3.78 Billion | -17.22 Billion | -3.89 Billion | -4.4 Billion | -4.93 Billion |
| Earnings Per Share Basic | -70.20 | -53.20 | - | -53.57 | -59.80 | -70.00 |
| Earnings Per Share Diluted | -70.20 | -53.20 | - | -53.57 | -59.80 | -70.00 |
| Weighted Average Shares Outstanding | 75.16 Million | 71.11 Million | 71.7 Million | 72.69 Million | 73.67 Million | 70.43 Million |
| Weighted Average Shares Outstanding (Diluted) | 75.16 Million | 71.11 Million | 71.7 Million | 72.69 Million | 73.67 Million | 70.43 Million |
| Gross Margin | 0.10 | 0.13 | 0.11 | 0.09 | 0.11 | 0.11 |
| EBIT Margin | -5.39 | -2.91 | - | -4.83 | -2.17 | -6.57 |
| Profit Margin | -5.50 | -3.12 | -4.65 | -5.04 | -2.52 | -7.45 |
| EBITDA | -5.16 Billion | -3.53 Billion | - | -3.72 Billion | -3.8 Billion | -4.34 Billion |
| Earnings Before Tax Margin | -5.61 | -3.50 | -5.53 | -7.16 | -2.96 | -8.12 |
129260
JELLF
YUKEN
RSE
CANSF
293780